Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Withdrawn 2Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Uterine Cervical Neoplasms 1Stomatitis 1Neutropenia 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

Cyclophosphamide 10fludarabine phosphate 9Rituximab 9Cytarabine 9Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Filgrastim 6Cyclosporine 6fludarabine 5Radiotherapy 5Busulfan 5Tacrolimus 4Mycophenolic Acid 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4Bendamustine Hydrochloride 4venetoclax 3duvelisib 3Whole-Body Irradiation 3Sirolimus 3Melphalan 3Antilymphocyte Serum 3Prednisone 2N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 2Mitoxantrone 2Lenalidomide 2Interferon-alpha 2Drug Therapy 2Clofarabine 2Arsenic Trioxide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Leukemia × Amifostine × Clear all
NCT00003407 2023-02-02

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Rush University Medical Center

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Drug-Related Side Effects and Adverse Reactions

NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡